BRCA mutation in high grade epithelial ovarian cancers

Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn, Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn

Abstract

Objective: To identify the frequency of BRCA mutation in patients with high grade epithelial ovarian cancer (EOC).

Methods: Patients with EOC included fallopian tube cancer or peritoneal cancer with high grade serous or high grade endometrioid were recruited. BRCA1 and BRCA2 mutations were tested and analyzed by next generation sequencing system.

Results: A total of 87 patients were recruited; majority of them (88.5%) were EOC, 5.7% fallopian tube cancer, 4.6% peritoneal cancer, and 1.1% synchronous primary ovarian and endometrial cancer. Seventy-four patients (85.1%) had high grade serous carcinoma and 13 patients (14.9%) had high grade endometrioid carcinoma. Germline BRCA mutation was detected in 19 patients (21.8%); 14 patients (16.1%) had BRCA1 mutation and 5 patients (5.7%) had BRCA2 mutation. All BRCA mutations were found in patients with high grade serous carcinoma (25.7%) but none in high grade endometrioid carcinoma. Six from 19 patients (31.6%) who had BRCA mutation had no family history of breast and ovarian cancers. Higher frequency of BRCA mutation was detected in patients with fallopian tube cancer; 3 in 5 patients (60%) followed by peritoneal cancer; 2 in 4 patients (50%), and EOC; 14 in 77 patients (18.2%).

Conclusion: The frequency of BRCA mutation in high grade serous carcinoma was 25.7%, none was found in high grade endometrioid carcinoma. High cost, unavailability of genetic testing, limited number of geneticists, may be barriers in limited resource countries. Selected patients especially high grade serous carcinoma should be considered initially.

Keywords: BRCA mutation; Epithelial ovarian cancer; High grade endometrioid carcinoma; High grade serous carcinoma.

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Alsop K., Fereday S., Meldrum C., deFazio A., Emmanuel C., George J. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J. Clin. Oncol. 2012;30:2654–2663.
    1. Arts-de Jong M., de Bock G.H., van Asperen C.J., Mourits M.J., de Hullu J.A., Kets C.M. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur. J. Cancer. 2016;61:137–145.
    1. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
    1. Chao A., Chang T.C., Lapke N. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 2016;7:85529–85541.
    1. Chirasophon S., Manchana T., Teerapakpinyo C. High-risk epithelial ovarian cancer patients for hereditary ovarian cancer. J. Obstet. Gynaecol. Res. 2017;43:929–934.
    1. Choi M.C., Heo J.H., Jang J.H. Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations. Int. J. Gynecol. Cancer. 2015;25:1386–1391.
    1. Choi M.C., Bae J.S., Jung S.G., Park H., Joo W.D., Song S.H. Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube. J. Gynecol. Oncol. 2018;29(4)
    1. Evans T., Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther. Adv. Med. Oncol. 2017;9:253–267.
    1. Hasmad H.N., Lai K.N., Wen W.X. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients. Gynecol. Oncol. 2016;141:318–322.
    1. Helpman L., Zidan O., Friedman E., Kalfon S., Perri T., Ben-Baruch G. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. J. Gynecol. Oncol. 2017;28(5)
    1. Hennessy B.T., Timms K.M., Carey M.S., Gutin A., Meyer L.A., Flake D.D., 2nd Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 2010;28:3570–3576.
    1. Ledermann J.A., Drew Y., Kristeleit R.S. Homologous recombination deficiency and ovarian cancer. Eur. J. Cancer. 2016;60:49–58.
    1. Levine D.A., Argenta P.A., Yee C.J., Marshall D.S., Olvera N., Bogomolniy F. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol. 2003;21:4222–4227.
    1. Lim M.C., Kang S., Seo S.S., Kong S.Y., Lee B.Y., Lee S.K. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J. Cancer Res. Clin. Oncol. 2009;135:1593–1599.
    1. Mafficini A., Simbolo M., Parisi A., Rusev B., Luchini C., Cataldo I. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget. 2016;7:1076–1083.
    1. Manchana T., Kobwitaya K. Survival outcomes for different subtypes of epithelial ovarian cancer. Clin. Res. Obstet. Gynecol. 2018;1:1–7.
    1. Pal T., Permuth-Wey J., Betts J.A., Krischer J.P., Fiorica J., Arango H. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807–2816.
    1. Richards S., Aziz N., Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405–424.
    1. Rojas V., Hirshfield K.M., Ganesan S., Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int. J. Mol. Sci. 2016 Dec 15;17:12. (pii: E2113)
    1. Sakamoto I., Hirotsu Y., Nakagomi H. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. Cancer. 2016;122:84–90.
    1. Wu X., Wu L., Kong B., Liu J., Yin R., Wen H. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. Int. J. Gynecol. Cancer. 2017;27:1650–1657.
    1. Zhang S., Royer R., Li S., McLaughlin J.R., Rosen B., Risch H.A. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 2011;121:353–357.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren